| Primary |
| Drug Use For Unknown Indication |
45.0% |
| Product Used For Unknown Indication |
34.3% |
| Prophylaxis |
5.2% |
| Thrombosis Prophylaxis |
3.2% |
| Anticoagulant Therapy |
1.9% |
| Hypertension |
1.4% |
| Haemodialysis |
1.4% |
| Coronary Artery Bypass |
0.9% |
| Pain |
0.8% |
| Peritoneal Dialysis |
0.7% |
| Diabetes Mellitus |
0.7% |
| Anaemia |
0.6% |
| Renal Failure Chronic |
0.6% |
| Intravenous Catheter Management |
0.5% |
| Catheterisation Cardiac |
0.5% |
| Blood Pressure |
0.5% |
| Cystitis Interstitial |
0.5% |
| Pulmonary Embolism |
0.5% |
| Deep Vein Thrombosis |
0.5% |
| Cardiac Disorder |
0.4% |
|
| Vomiting |
27.6% |
| Hypotension |
12.4% |
| Nausea |
7.0% |
| Heparin-induced Thrombocytopenia |
5.2% |
| Death |
4.4% |
| Drug Ineffective |
4.4% |
| Tachycardia |
4.1% |
| Adverse Event |
3.7% |
| Thrombosis |
3.5% |
| Unresponsive To Stimuli |
3.5% |
| Blood Pressure Decreased |
3.1% |
| Thrombocytopenia |
3.0% |
| Haemorrhage |
2.8% |
| Paraesthesia Oral |
2.8% |
| Thirst |
2.7% |
| Sepsis |
2.2% |
| Rash |
2.2% |
| Urticaria |
1.9% |
| Vision Blurred |
1.8% |
| Malaise |
1.7% |
|
| Secondary |
| Product Used For Unknown Indication |
54.0% |
| Drug Use For Unknown Indication |
31.4% |
| Thrombosis Prophylaxis |
2.9% |
| Haemodialysis |
1.8% |
| Prophylaxis |
1.5% |
| Catheterisation Cardiac |
1.0% |
| Intravenous Catheter Management |
0.9% |
| Coronary Artery Bypass |
0.8% |
| Pain |
0.6% |
| Hypertension |
0.6% |
| Anticoagulant Therapy |
0.6% |
| Ill-defined Disorder |
0.6% |
| Atrial Fibrillation |
0.5% |
| Intra-aortic Balloon Placement |
0.5% |
| Pulmonary Embolism |
0.5% |
| Asthma |
0.4% |
| Acute Myocardial Infarction |
0.4% |
| Peritoneal Dialysis |
0.4% |
| Pyrexia |
0.3% |
| Deep Vein Thrombosis |
0.3% |
|
| Vomiting |
41.3% |
| Thrombocytopenia |
5.7% |
| Hypotension |
5.3% |
| Paraesthesia Oral |
4.9% |
| Thrombosis |
4.8% |
| Unresponsive To Stimuli |
4.5% |
| Wound Secretion |
4.4% |
| Nausea |
3.5% |
| Tachycardia |
3.1% |
| Sepsis |
2.8% |
| Ocular Hyperaemia |
2.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.3% |
| Ventricular Fibrillation |
2.2% |
| Renal Failure |
1.9% |
| Urinary Tract Infection |
1.9% |
| Vascular Pseudoaneurysm |
1.8% |
| Septic Shock |
1.8% |
| Syncope |
1.7% |
| Headache |
1.6% |
| Paraesthesia |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.9% |
| Prophylaxis |
12.4% |
| Drug Use For Unknown Indication |
9.7% |
| Hypertension |
6.1% |
| Infection Prophylaxis |
3.6% |
| Premedication |
3.4% |
| Constipation |
3.4% |
| Diabetes Mellitus |
2.8% |
| Stem Cell Transplant |
2.7% |
| Pain |
2.7% |
| Coronary Artery Bypass |
2.4% |
| Angina Pectoris |
2.2% |
| Cerebral Infarction |
2.2% |
| Thrombosis Prophylaxis |
2.1% |
| Castleman's Disease |
1.9% |
| Multiple Myeloma |
1.9% |
| Pneumonia |
1.9% |
| Prophylaxis Against Graft Versus Host Disease |
1.8% |
| Acute Coronary Syndrome |
1.7% |
| Acute Myocardial Infarction |
1.4% |
|
| White Blood Cell Count Decreased |
16.5% |
| Renal Impairment |
7.9% |
| Pain |
6.6% |
| Renal Failure |
5.6% |
| Renal Failure Acute |
5.4% |
| Injury |
5.2% |
| Sepsis |
5.0% |
| Thrombocytopenia |
4.7% |
| Vomiting |
4.3% |
| Rhabdomyolysis |
4.1% |
| Pneumonia |
3.9% |
| Cerebral Infarction |
3.8% |
| Pyrexia |
3.8% |
| Respiratory Failure |
3.8% |
| Liver Function Test Abnormal |
3.6% |
| Death |
3.4% |
| White Blood Cell Count Increased |
3.4% |
| Anxiety |
3.2% |
| Platelet Count Decreased |
2.9% |
| Unevaluable Event |
2.9% |
|
| Interacting |
| Angina Pectoris |
27.3% |
| Angioplasty |
13.0% |
| Acute Myocardial Infarction |
7.8% |
| Drug Use For Unknown Indication |
5.2% |
| Thrombosis Prophylaxis |
5.2% |
| Abdominal Pain Upper |
3.9% |
| Benign Prostatic Hyperplasia |
3.9% |
| Hypertension |
3.9% |
| Leriche Syndrome |
3.9% |
| Pulmonary Embolism |
3.9% |
| Acute Promyelocytic Leukaemia |
2.6% |
| Anticoagulant Therapy |
2.6% |
| Arterial Stenosis |
2.6% |
| Coronary Artery Disease |
2.6% |
| Pain |
2.6% |
| Peripheral Ischaemia |
2.6% |
| Uterine Cancer |
2.6% |
| Arterial Catheterisation |
1.3% |
| Atrial Flutter |
1.3% |
| Diabetic Nephropathy |
1.3% |
|
| Drug Interaction |
20.7% |
| Subdural Haemorrhage |
13.8% |
| Haemorrhage |
10.3% |
| Coagulopathy |
6.9% |
| Drug Level Decreased |
6.9% |
| Retroperitoneal Haematoma |
6.9% |
| Atrial Flutter |
3.4% |
| Coagulation Test Abnormal |
3.4% |
| Increased Tendency To Bruise |
3.4% |
| International Normalised Ratio Increased |
3.4% |
| Myositis |
3.4% |
| Pleural Effusion |
3.4% |
| Puncture Site Haemorrhage |
3.4% |
| Respiratory Disorder |
3.4% |
| Shock Haemorrhagic |
3.4% |
| Subarachnoid Haemorrhage |
3.4% |
|
